RecruitingNCT05555433

Calprotectine in Spondyloarthritis

Study of the Interest of Serum Calprotectin Determination in the Diagnosis of Spondyloarthritis and to Diferenciate With Fibromyalgia

Sponsor

Centre Hospitalier Universitaire de Nice

Enrollment

190 participants

Start Date

Aug 15, 2022

Study Type

OBSERVATIONAL

Conditions

Spondylarthritis

Summary

To date, there are no biomarkers in spondyloarthritis that can differentiate between spondyloarthritis and fibromyalgia or other pathologies. Fecal calprotectin is a biomarker that is increasingly used in inflammatory diseases of the digestive tract. A growing interest in this biomarker is emerging in rheumatology, several publications have focused on its interest in rheumatoid arthritis, highlighting an association between serum calprotectin levels and disease activity. In spondyloarthritis, a few studies seem to show that it could be a marker of disease activity. Although a 2012 study found no difference in serum calprotectin levels between subjects with spondyloarthritis and controls. Still others have shown that it could be a predictive factor of radiological evolution in the same disease key. These data support, despite the questionable results of the Klingberg study, the value of this dosage in spondyloarthritis. The objective of this work is to show that this assay could be useful to differentiate spondyloarthritis from other pathologies with similar clinical presentation such as fibromyalgia. Difficulties classically encountered in common practice in rheumatology

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is measuring calprotectin levels — a protein marker of inflammation — in the stool and blood of patients with spondyloarthritis, fibromyalgia, and healthy individuals. Spondyloarthritis is a type of inflammatory arthritis that often affects the spine and can also involve the gut. By comparing calprotectin levels across different patient groups, researchers hope to better understand the link between gut inflammation and joint disease, which could improve how the condition is monitored. You may be eligible if: - You are 18 years of age or older - You have active spondyloarthritis (BASDAI score greater than 4), low-activity spondyloarthritis (BASDAI less than 4), fibromyalgia without inflammatory rheumatism, or you are a healthy control - You consent to the use of your samples You may NOT be eligible if: - You are under 18 years old - You are not affiliated with the social security system (study-specific requirement) - You have been deprived of liberty or are under legal guardianship Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.